Elamipretide is the active ingredient in Forzinity from Stealth BioTherapeutics. The label describes it as a mitochondrial cardiolipin binder that acts on the inner membrane of mitochondria, the energy-producing parts of cells.2,3 FDA granted it accelerated approval on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome, a rare genetic disease, who weigh at least 30 kg.2,3 The approval rests on an improvement in knee muscle strength, an intermediate measure, seen in the open-label extension of a 12-person trial that did not meet its main goals. FDA requires a confirmatory randomized trial.2,3
Elamipretide at a glance
What it is
A peptide that the label describes as a mitochondrial cardiolipin binder that improves mitochondrial structure and function.3
FDA status
FDA-approved. FDA’s September 19, 2025 accelerated approval letter approves Forzinity for a specified Barth syndrome population and requires a trial to verify clinical benefit. The label has no boxed warning.2,3
Human evidence
One small randomized, placebo-controlled crossover trial in 12 people that missed its main goals, followed by an open-label extension, as described in the label.3
Evidence strength
Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned
What is elamipretide?
Elamipretide is the active ingredient of Forzinity. The label describes it as a mitochondrial cardiolipin binder, isolated as a hydrochloride salt.3
It is also known by the development names SS-31 and MTP-131.1
FDA’s approval letter is addressed to Stealth BioTherapeutics for application NDA 215244.2
How does elamipretide work?
The label describes Forzinity as a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial structure and function.3
The label states that the approval is based on an improvement in knee muscle strength, which it calls an intermediate clinical endpoint, rather than on a direct measure of how people feel or function.3
What do human studies show?
The label describes a randomized, double-blind, placebo-controlled crossover trial in 12 people aged 12 or older with genetically confirmed Barth syndrome. Elamipretide was not superior to placebo on the main outcomes, the 6-minute walk distance and a fatigue score.3
Knee muscle strength did not increase during the randomized trial, but increases were observed during the open-label extension, according to the label. Ten participants entered the extension and eight took part through week 168.3
The label presents the extension results as descriptive changes from the starting measurement, without a placebo comparison.3
What the evidence base contains
Controlled human trial A randomized, double-blind, placebo-controlled crossover trial in 12 people aged 12 or older with Barth syndrome. The label states that elamipretide was not superior to placebo on its main outcomes, walking distance and fatigue.3
Small, short, or incompletely reported human study An open-label, single-arm extension in which 10 of those participants continued and 8 took part through week 168, with increases in knee muscle strength reported.3
Registered trial without results A further Barth syndrome trial, 4TAZPower (NCT07531251), sponsored by Stealth BioTherapeutics and listed as recruiting in its July 13, 2026 registry record.1
A Federal Register notice announced that an FDA advisory committee would discuss the elamipretide application for Barth syndrome at an October 10, 2024 meeting.4
Yes, under accelerated approval. FDA’s letter of September 19, 2025 grants Forzinity accelerated approval, effective on the date of the letter, under FDA’s accelerated approval rules.2
The Forzinity label cited here (revised September 2025) states that it is indicated to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg, and that continued approval may depend on a confirmatory trial.3
The approval letter requires a randomized, double-blind, placebo-controlled trial in people aged 5 and older with Barth syndrome to verify the clinical benefit, and states that FDA may withdraw the approval if the trial fails to do so. FDA also granted a rare pediatric disease priority review voucher.2
The label has no boxed warning. It states that Forzinity is contraindicated in people with serious allergic reactions to it, and its warnings cover allergic reactions and the risk of benzyl alcohol toxicity in newborns; it is not approved for newborns.3
Timeline
A Federal Register notice announces an October 10, 2024 FDA advisory committee meeting on the elamipretide application for Barth syndrome.4
FDA grants Forzinity accelerated approval for a specified Barth syndrome population.2
The 4TAZPower trial record is updated on ClinicalTrials.gov, listing the trial as recruiting.1
What is still unknown?
Whether the improvement in muscle strength translates into clinical benefit, which FDA’s required confirmatory trial is meant to show.2,3
Its effects in people outside the approved group: the label covers Barth syndrome in people weighing at least 30 kg.3
Results of the 4TAZPower trial, which was recruiting in its July 13, 2026 registry record.1
Compare and browse
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Records, reviews and history
Everything PeptideScanner has collected for Elamipretide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Elamipretide are the records PeptideScanner has selected and published, not every registration or paper about Elamipretide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.
Status brief and reviewed-evidence summary
Evidence summary
What the cited records show
What is its status in the cited records?
FDA-approved as Forzinity under accelerated approval for Barth syndrome. The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.↗↗
Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.
Three selected reports cover the randomized Barth syndrome study, follow-up of the same cohort, and a separate primary mitochondrial myopathy trial. They do not cover every indication or replace the product-specific regulatory record.↗↗↗
What the reviewed sources report
The randomized Barth syndrome study did not meet its two primary endpoints; later uncontrolled follow-up reported improvements. The larger MMPOWER-3 trial in primary mitochondrial myopathy also missed its primary endpoints. These populations and study designs must be considered separately.↗↗↗
What remains unresolved?
Which confirmatory results establish clinical benefit in the Barth syndrome population?↗↗↗
How do study population, attrition and the absence of a control group affect the extension findings?↗↗↗
The label covers improved muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Accelerated approval rests on an intermediate clinical endpoint and requires confirmation of clinical benefit. Label: 1 ↗
Which safety limits matter?
The label contraindicates serious hypersensitivity and warns about hypersensitivity reactions and benzyl-alcohol toxicity in neonates. Injection-site reactions were the most common adverse reactions. Label: 4, 5, 6 ↗
Label edition and source pins
FDA-hosted U.S. prescribing information. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
Three selected reports cover the randomized Barth syndrome study, follow-up of the same cohort, and a separate primary mitochondrial myopathy trial. They do not cover every indication or replace the product-specific regulatory record.123
Bottom line from this bounded source set
The randomized Barth syndrome study did not meet its two primary endpoints; later uncontrolled follow-up reported improvements. The larger MMPOWER-3 trial in primary mitochondrial myopathy also missed its primary endpoints. These populations and study designs must be considered separately.123
Reviewed study record
TAZPOWER: randomized and early extension results
Design
A blinded placebo-controlled crossover trial was followed by an open-label extension.1
Population
Twelve participants with Barth syndrome entered the randomized study; ten entered the extension and eight reached 36 weeks.1
Outcomes reported
Neither primary endpoint was met in the randomized period. Walking distance and reported fatigue improved during the uncontrolled extension.1
Limitations
The extension lacks a concurrent placebo group and has attrition. Its changes cannot be interpreted as another randomized treatment effect; the abstract does not provide a detailed harms assessment.1
Reviewed study record
TAZPOWER: longer follow-up of the same cohort
Design
An open-label extension followed participants for up to 168 weeks.2
Population
Ten participants entered the extension; eight reached the week-168 visit.2
Outcomes reported
The authors reported improvements in walking distance and fatigue assessments. Injection-site reactions were the most common adverse events.2
Limitations
This is follow-up of TAZPOWER, not an independent trial. Selection, attrition and absence of concurrent controls limit attribution and generalizability.2
Reviewed study record
MMPOWER-3: primary mitochondrial myopathy
Design
A randomized, blinded, placebo-controlled phase 3 trial assessed 24-week outcomes.3
Population
The study randomized 218 participants with genetically confirmed primary mitochondrial myopathy.3
Outcomes reported
Neither walking distance nor fatigue met the primary efficacy endpoint. Most reported adverse events were mild or moderate.3
Limitations
This is a different disease population from Barth syndrome. Overall null results cannot be replaced by favorable exploratory subgroup findings.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1038/s41436-020-01006-8. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/j.gim.2024.101138. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1212/wnl.0000000000207402. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
The randomized trial did not meet its primary endpoints
FDA’s 2025 review reports that the 12-participant, placebo-controlled crossover study did not show superiority on six-minute walk distance or fatigue. The two 12-week treatment periods and later open-label follow-up answer different questions. FDA PDF pp. 3, 85 ↗
More findings, study links and document coverage
Why the accelerated-approval decision differed
The signatory accepted sustained knee-extension strength findings despite the review team’s recommendation against approval. The decision acknowledged substantial uncertainty from unblinded assessment, attrition and the absence of a concurrent control in the extension. FDA PDF pp. 3, 4 ↗
Muscle strength was an intermediate clinical endpoint
FDA distinguished the knee-extensor measurement from demonstrated improvement in how patients function. Accelerated approval used knee-extensor strength as an intermediate clinical endpoint and required a trial to confirm clinical benefit; this document does not establish that trial’s subsequent outcome. FDA PDF pp. 4 ↗
The scope is Barth syndrome
This assessment concerns Forzinity in Barth syndrome. Neither its decision nor the extension findings establish efficacy for unrelated mitochondrial conditions or general performance enhancement. FDA PDF pp. 2, 3, 4 ↗
Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.
Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗
Inspect documents, application identities and source pins
Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.
Independently retrieved FDA approval-package PDF. The displayed date belongs to the selected review, not the entire compilation or a current label.
Verified: Forzinity · NDA 215244 · Document dated 2025-09-19. Identity checked on PDF pp. 1, 2.
Identity and selected clinical design, efficacy, safety and benefit-risk sections only. One-based PDF file pages; unlisted pages have not been appraised. The date identifies the selected review within any compiled approval package.
Retrieved 2026-09-19. Read PDF pages: 1, 2, 3, 4, 85 of 378. SHA-256: 354af3d2efb096379db185bcbd181635c91bbe0c1a3a2327c375a16f820f2415.
Remaining work
Read the full integrated efficacy and safety sections, and reconcile the confirmatory-trial record and later regulatory updates.
Keep other mitochondrial-disease trials separate from the Barth syndrome evidence.
Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.
Primary reports of administration to people of the specified peptide; secondary reviews, animal/cell experiments and unrelated acronym matches are outside this scope. Selected summaries do not close the broader screening queue.
447 retrieved · 3 included · 0 excluded · 444 awaiting a decision · 2 full-text appraisals
Search terms, record decisions and remaining work
"elamipretide"[Title/Abstract] OR "SS-31"[Title/Abstract] OR "MTP-131"[Title/Abstract] OR "Forzinity"[Title/Abstract]
Search covers PubMed title/abstract terms; regulator, registry, older aliases, non-indexed and non-English records require separate reconciliation.
Full-text appraisal and independent registry comparison remain incomplete.
Showing 25 of 447 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
PubMed 38602181 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT03098797.
PubMed 37268435 — include: Selected human report; main full text and current registry comparison reviewed. Specific supplements, historical comparisons and unresolved issues remain identified in the structured reading. Study families: NCT03323749.Structured full-text reading · PMC10382259
This is an editorial structured reading, not a validated risk-of-bias score.
MMPOWER-3 used computer-generated assignment, genotype stratification and identical vials; participants, investigators, pharmacists and sponsor were blinded. There were 218 randomized participants, 109 per group.
Missing data
The paper reports 205 completing 24 weeks and uses mixed-model repeated measures in the treated population. Text and figure disagree on per-protocol counts; that discrepancy remains unresolved. Adverse-event discontinuations were eight versus two, a different measure from completion.
Outcome selection
Neither coprimary endpoint improved: the between-group six-minute walk difference was -3.2 m (95% CI -18.7 to 12.3), and fatigue also missed significance. A post hoc genotype subgroup signal does not reverse the primary result. The paper reports five versus three serious adverse events, attributed as unrelated by investigators.
Applicability
Participants had ambulatory primary mitochondrial myopathy; 94% were White and 64% female. Eligibility, baseline walking ability and mostly mild-to-moderate fatigue restrict generalization. This is a different population from the Barth syndrome indication.
Funding and conflicts
Stealth BioTherapeutics funded and helped design the study. Sponsor staff and compensated consultants were among the authors; the lead author had full data access and others received aggregate data.
Registry comparison
The retained NCT03323749 record agrees on the two 24-week primary outcomes and reports termination after primary endpoint failure. Secondary-outcome history and linked supplements have not been fully reconciled. The current record is not a complete historical protocol audit.
PubMed 33077895 — include: Selected human report; main full text and current registry comparison reviewed. Specific supplements, historical comparisons and unresolved issues remain identified in the structured reading. Study families: NCT03098797.Structured full-text reading · PMC7935714
This is an editorial structured reading, not a validated risk-of-bias score.
SPIBA-201 used independent randomization and identical packaging in a blinded crossover: two 12-week periods separated by washout. All 12 participants completed both randomized periods.
Missing data
Ten entered the uncontrolled extension; two stopped after injection-site reactions and eight contributed week-36 outcomes. Extension improvements therefore describe a selected continuing group, not all randomized participants.
Outcome selection
The randomized walking and fatigue coprimary outcomes were null; the walking difference was -0.8 m (p=0.97). Extension efficacy was secondary and based on within-person changes. One randomized-period serious event, hospitalization for costochondritis, was reported as unrelated; absence of serious harm is not supported.
Applicability
This single-site study enrolled ambulatory males aged at least 12 with genetically confirmed Barth syndrome. It cannot establish effects in infants or all disease severities. Uncontrolled extension results remain vulnerable to learning effects and other changes over time.
Funding and conflicts
Stealth BioTherapeutics funded the study and contributed to design, analysis and writing, but not data collection, according to the authors.
Registry comparison
NCT03098797 matches the 12-participant crossover and randomized walking/fatigue outcomes. The 168-week publication follows the same study family. Supplementary outcome definitions and the complete registry history remain unreviewed; extension exposure duration must not be confused with calendar follow-up.
PubMed 42357949 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42600764 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42473606 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42709510 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42448476 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42324025 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42242082 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42708867 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42638278 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42676996 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42570043 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42546889 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42361626 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42290373 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 41966639 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 41934921 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 41233677 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42456009 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42443448 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42358073 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42415111 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
PubMed 42359884 — not screened: Retrieved for the broader search; eligibility has not yet been adjudicated.
ClinicalTrials.gov search
ClinicalTrials.gov API v2 identity-name search, complete retrieved records. Includes protocols, extensions, combinations and expanded access; these are not all efficacy trials or published outcomes.
32 retrieved · 30 included · 2 excluded · 0 awaiting a decision · 0 full-text appraisals
Registry identity screening is distinct from appraisal of posted results, protocol history and publication linkage.
Other registries and unregistered studies are outside this search.
Showing 25 of 32 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
ClinicalTrials.gov NCT02848313 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02848313.
ClinicalTrials.gov NCT07531251 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07531251.
ClinicalTrials.gov NCT07275424 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT07275424.
ClinicalTrials.gov NCT02693119 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02693119.
ClinicalTrials.gov NCT02805790 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02805790.
ClinicalTrials.gov NCT02914665 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02914665.
ClinicalTrials.gov NCT01754818 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01754818.
ClinicalTrials.gov NCT01755858 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01755858.
ClinicalTrials.gov NCT05162768 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05162768.
ClinicalTrials.gov NCT02976038 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02976038.
ClinicalTrials.gov NCT01115920 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01115920.
ClinicalTrials.gov NCT03891875 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT03891875.
ClinicalTrials.gov NCT01572909 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01572909.
ClinicalTrials.gov NCT02436447 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02436447.
ClinicalTrials.gov NCT02814097 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02814097.
ClinicalTrials.gov NCT05168774 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT05168774.
ClinicalTrials.gov NCT01513200 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01513200.
ClinicalTrials.gov NCT02388464 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02388464.
ClinicalTrials.gov NCT02314299 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02314299.
ClinicalTrials.gov NCT01518985 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01518985.
ClinicalTrials.gov NCT03323749 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT03323749.
ClinicalTrials.gov NCT02653391 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02653391.
ClinicalTrials.gov NCT02367014 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02367014.
ClinicalTrials.gov NCT01786915 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT01786915.
ClinicalTrials.gov NCT02245620 — include: The intervention record names this molecule or its validated development code. Eligibility here is registry identity matching; outcomes and applicability remain separately unappraised. Study families: NCT02245620.
FDA search
Exact active-ingredient terms in the openFDA Drugs@FDA endpoint, checked September 15. A zero result describes this indexed query only, not worldwide nonapproval or every FDA document.
1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Search terms, record decisions and remaining work
products.active_ingredients.name:"ELAMIPRETIDE" OR products.active_ingredients.name:"ELAMIPRETIDE HYDROCHLORIDE"
This query does not cover all FDA safety communications, labels, compounding proceedings or other regulatory systems.
Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
FDA NDA215244 — include: The application record contains the queried ingredient; indications, labels and approval documents require their own review.
EMA search
Local identity matching in the pinned EMA medicines metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA documents metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA search
Local identity matching in the pinned EMA orphans metadata feed. This feed is not every national European authorization or every agency document; orphan designation is not marketing authorization.
2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals
Complete source-document appraisal and national European sources remain open.
Zero identity matches apply only to these feed fields and terms.
Direct orphan document pages were unavailable during review; only feed metadata is retained.
Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.
EMA EU/3/21/2430 — include: EMA orphan metadata identifies elamipretide for Treatment of Barth syndrome. This designation does not establish marketing authorization.
EMA EU/3/22/2614 — include: EMA orphan metadata identifies elamipretide for Treatment of myopathic mitochondrial DNA depletion syndrome. This designation does not establish marketing authorization.
Explore status sources, recent additions, and coverage gaps
Living status brief
What is the current status of Elamipretide?
FDA-approved as Forzinity under accelerated approval for Barth syndrome. The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.↗↗
The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.
PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.
Regulatory and publication surfaces
What is structurally connected?
Drugs@FDA applications
0
FDA Federal Register documents
2
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
51
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Profile publication history and record countsTrial–publication links · 1
These links come only from structured NCT and PMID identifiers declared by PubMed or ClinicalTrials.gov. They do not summarize the publications or establish findings.
ClinicalTrials.gov posted a newer version of NCT07531251, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting.
PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide.
Selected records span November 21, 2013 to November 10, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
PeptideScanner retained ClinicalTrials.gov record NCT07927972 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was elamipretide.↗
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.↗
PubMed lists PMID 42708867 in Physiological research as Journal Article, Comparative Study, with publication-date metadata of 2026-08-31 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42456009 at 2026-08-10T18:13:55.284Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 35611788 at 2026-08-10T18:13:32.311Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2022-05-25. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42450582 at 2026-08-10T18:13:55.269Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-15. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42219795 at 2026-08-10T18:13:50.715Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-06-01. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42448476 at 2026-08-10T18:13:55.255Z. PubMed recorded a metadata revision date of 2026-07-14 and an Entrez history date of 2026-07-14. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 42443448 at 2026-08-10T18:13:55.249Z. PubMed recorded a metadata revision date of 2026-07-13 and an Entrez history date of 2026-07-13. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 41801306 at 2026-08-10T18:13:44.801Z. PubMed recorded a metadata revision date of 2026-07-10 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗
PeptideScanner retained PubMed bibliographic metadata for PMID 38237649 at 2026-08-10T18:13:32.340Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2024-01-18. PeptideScanner associated this retained record with the identity slug elamipretide. These dates describe PubMed metadata history, not the article's original publication date.↗